Portola Pharmaceuticals, Inc. Announces Initiation of Phase 1/2 Clinical Study of PRT2070

Published: Oct 09, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it has initiated a Phase 1/2 clinical study of PRT2070, a novel, oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor. The compound is being developed for patients with genetically-defined hematologic cancers, as well as for patients who have failed therapy due to relapse or acquired mutations. PRT2070's dual mechanism of action, which targets two validated pathways for tumor survival and proliferation, has strong scientific rationale in these settings, where other compounds have failed to demonstrate clinical benefit.

Help employers find you! Check out all the jobs and post your resume.

Back to news